Carol Ann Huff
The Johns Hopkins University · Sidney Kimmel Cancer Center at Johns Hopkins Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Carol Ann Huff as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:07 UTC. Open this list on ClinicalTrials.gov
- Early Ph1NCT01861340 · Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple MyelomaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Myeloma · principal investigator
- Ph2NCT01242930 · Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple MyelomaGeron Corporation · completed · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:07 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Role of multiple myeloma cancer stem cells in clinical diseaseR01CA174951 · NCI · JOHNS HOPKINS UNIVERSITY · fiscal years 2014 to 2018 · $580,232 awarded in 2018Same name and institution; not confirmed by an ID
- Biostatistics and Data ManagementP01CA015396 · NCI · JOHNS HOPKINS UNIVERSITY · fiscal years 2011 · $571,859 awarded in 2011Same name and institution; not confirmed by an ID
- HIGH DOSE CYCLOPHOSPHAMIDE AND RITUXIMAB IN MULTIPLE MYELOMAM01RR000052 · NCRR · JOHNS HOPKINS UNIVERSITY · fiscal years 2006 to 2007 · $1,238 awarded in 2007Same name and institution; not confirmed by an ID
- Translational Research in Multiple MyelomaK23CA093657 · NCI · JOHNS HOPKINS UNIVERSITY · fiscal years 2002 to 2006 · $136,890 awarded in 2006Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:07 UTC. The ranking covers the 200 most relevant of 20 PubMed records, and a shared surname and initials can bring in a namesake. All 20 on PubMed
- HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.Biol Blood Marrow Transplant · 20081,643 citationsRCR 39.2
- Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.N Engl J Med · 2019550 citationsRCR 19.6
- High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.Blood · 2010340 citationsRCR 8.5
- A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.Br J Haematol · 2018147 citationsRCR 5.0
- Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.J Clin Oncol · 2018140 citationsRCR 4.6
- Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial.Lancet Haematol · 2019133 citationsRCR 6.4
- Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses.Clin Cancer Res · 2012108 citationsRCR 2.6
- Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma.Sci Transl Med · 2015107 citationsRCR 2.9
- 100 citationsRCR 2.8
- Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions.Biol Blood Marrow Transplant · 200652 citationsRCR 1.2